Pulmonary Embolism – Evidence‑Based Diagnosis and Management

Diagnosis

Clinical Probability Assessment

Use validated prediction rules to stratify patients into low, intermediate, or high clinical probability before any testing; this guides subsequent D‑dimer use and imaging. European Society of Cardiology (ESC) guideline 1
Immediately assess for hemodynamic instability (shock or systolic BP < 90 mm Hg) to identify high‑risk PE that requires urgent therapy. ESC guideline 1
Both three‑level (low/intermediate/high) and two‑level (PE unlikely/PE likely) schemes are acceptable for clinical probability assessment. ESC guideline 1

D‑dimer Testing

Measure D‑dimer only in patients with low or intermediate clinical probability (or “PE unlikely”) and use highly sensitive assays. ESC guideline 1, 2
Do not measure D‑dimer in patients with high clinical probability; a normal result does not safely exclude PE. ESC guideline 1, 2

Imaging

Computed tomography pulmonary angiography (CTPA) is the first‑choice imaging test for hemodynamically stable patients with an elevated D‑dimer or high clinical probability. ESC guideline 1
Accept a PE diagnosis when CTPA shows a segmental or more proximal filling defect in patients with intermediate or high clinical probability. ESC guideline 1, 2
Reject a PE diagnosis when CTPA is normal in patients with low or intermediate clinical probability. ESC guideline 1, 2
Ventilation‑perfusion (V/Q) scintigraphy is a valid alternative when CTPA is contraindicated; a normal perfusion scan excludes PE. ESC guideline 1
Do not perform CT venography as an adjunct to CTPA. ESC guideline 1, 2
Do not use magnetic resonance angiography (MRA) to rule out PE. ESC guideline 1, 2
A proximal deep‑vein thrombosis identified by compression ultrasound in a patient with suspected PE confirms venous thromboembolism (VTE). ESC guideline 1, 2

Treatment

High‑Risk (Hemodynamically Unstable) PE

Administer systemic thrombolytic therapy immediately to all high‑risk patients without a high bleeding‑risk profile. ESC guideline 1
Initiate intravenous unfractionated heparin (UFH) without delay, using a weight‑adjusted bolus, even before imaging confirmation. ESC guideline 1, 2
If hemodynamic deterioration occurs despite anticoagulation, give rescue thrombolytic therapy. ESC guideline 1, 2
Surgical pulmonary embolectomy is indicated when thrombolysis is contraindicated or fails to improve hemodynamics within one hour. ESC guideline 1, 3

Intermediate‑ and Low‑Risk (Hemodynamically Stable) PE

Start anticoagulation immediately in patients with high or intermediate clinical probability while diagnostic work‑up proceeds. ESC guideline 1, 2
For parenteral anticoagulation in stable patients, prefer low‑molecular‑weight heparin (LMWH) or fondaparinux over UFH. ESC guideline 1, 2
Do not use systemic thrombolysis as routine primary treatment in intermediate‑ or low‑risk PE. ESC guideline 1, 2

Oral Anticoagulation Choice

Prefer a non‑vitamin‑K oral anticoagulant (NOAC) (apixaban, dabigatran, edoxaban, rivaroxaban) over a vitamin K antagonist (VKA) for initiating oral therapy. ESC guideline 1, 2
If a VKA is chosen, overlap with parenteral anticoagulation until the INR reaches 2.5 (target range 2.0–3.0). ESC guideline 1, 2
Do not use NOACs in patients with severe renal impairment or antiphospholipid antibody syndrome; these patients should receive a VKA indefinitely. ESC guideline 1, 2

Duration of Anticoagulation

All patients with PE require therapeutic anticoagulation for a minimum of 3 months. ESC guideline 1, 2
Provoked PE (first event associated with a major transient/reversible risk factor): discontinue anticoagulation after 3 months. ESC guideline 1, 2, 3
Unprovoked PE: consider extended anticoagulation beyond 3 months if bleeding risk is low or moderate; reassess regularly for tolerance, adherence, organ function, and bleeding risk. ESC guideline 1, 2
Recurrent VTE (≥ one prior PE or DVT not linked to a transient risk factor): continue oral anticoagulation indefinitely. ESC guideline 1, 2
Antiphospholipid antibody syndrome: continue VKA indefinitely. ESC guideline 1, 2
Pregnancy: use therapeutic fixed‑dose LMWH based on early‑pregnancy weight; NOACs are contraindicated during pregnancy and lactation. ESC guideline 2

Inferior Vena Cava (IVC) Filter Placement

Do not routinely place IVC filters. ESC guideline 1, 2
IVC filters are reserved for patients at high risk of further emboli who have a contraindication to anticoagulation or who experience recurrent PE despite adequate anticoagulation. ESC guideline 3

Critical Pitfalls to Avoid

Never delay anticoagulation in high‑ or intermediate‑probability cases while awaiting diagnostic confirmation. ESC guideline 1, 2
Never measure D‑dimer in patients with high clinical probability; proceed directly to imaging. ESC guideline 1, 2
Never use NOACs in patients with severe renal impairment or antiphospholipid syndrome; a VKA is mandatory. ESC guideline 1, 2

Management of Pulmonary Embolism

Initial Risk Stratification

The European Society of Cardiology recommends that patients with shock or hypotension (systolic blood pressure <90 mmHg) require urgent and aggressive treatment, while hemodynamically stable patients can be treated with standard anticoagulation 4, 5

High-Risk Pulmonary Embolism (Hemodynamic Instability)

The European Heart Journal suggests that unfractionated heparin should be initiated immediately, without delay, even before imaging confirmation in hemodynamically unstable patients 6, 5
The initial dose of unfractionated heparin is a bolus of 5,000-10,000 units followed by continuous infusion of 400-600 units/kg/day (or 30,000-40,000 units/24 hours) 5
Activated partial thromboplastin time (aPTT) should be maintained at 1.5-2.5 times the control value, measured 4-6 hours after treatment initiation 5
Unfractionated heparin is preferred over low-molecular-weight heparin (LMWH) or fondaparinux in patients with hemodynamic instability, as the latter have not been tested in the context of shock 6
Systemic thrombolysis should be administered immediately to all patients with pulmonary embolism and hypotension who do not have a high risk of bleeding 6, 5
Alteplase (rtPA) is the preferred agent: 0.6 mg/kg in 15 minutes (maximum 50 mg) or 100 mg in 2 hours 5
The benefit of thrombolysis: meta-analyses show a significant reduction in mortality or recurrence of pulmonary embolism in patients with massive pulmonary embolism (OR 0.45; 95% CI 0.22-0.92) 6
The risk of major bleeding: 21.9% in patients with massive pulmonary embolism treated with thrombolysis vs. 11.9% with heparin 6

Alternative Therapies

Surgical pulmonary embolectomy is the preferred therapy if thrombolysis is absolutely contraindicated or has failed to improve hemodynamic status 6, 5
Catheter embolectomy or thrombus fragmentation may be considered if surgery is not immediately available, although safety and efficacy are not well documented 6
Extracorporeal membrane oxygenation (ECMO) may be considered in extreme cases 5

Hemodynamic Support Measures

High-flow oxygen for correction of hypoxemia 5
Vasopressor agents are recommended for hypotensive patients 6
Dobutamine and dopamine may be used in patients with low cardiac output and normal blood pressure 6
Avoid aggressive fluid challenge - this may worsen right ventricular failure 6
Avoid diuretics and vasodilators as they may worsen cardiovascular collapse 5

Anticoagulation Therapy

The European Heart Journal recommends that the minimum duration of anticoagulation is 3 months for all cases of pulmonary embolism 4, 5
For unprovoked pulmonary embolism, consider extended anticoagulation after 3 months if the risk of bleeding is low or moderate 5
Oral anticoagulation should be continued indefinitely in patients who have had recurrent venous thromboembolism (at least one previous episode of pulmonary embolism or deep vein thrombosis) that is not related to a major transient or reversible risk factor 4

Monitoring and Post-Pulmonary Embolism Care

Reevaluate patients routinely at 3-6 months after acute pulmonary embolism 4, 7
Implement an integrated care model after acute pulmonary embolism to ensure optimal transition from hospital to ambulatory care 4, 7
Refer symptomatic patients with inadequate perfusion defects to ventilation-perfusion scintigraphy after 3 months of pulmonary embolism at a center of expertise in pulmonary hypertension, considering echocardiography, natriuretic peptide, and/or cardiopulmonary exercise testing results 4, 7

Management of Pulmonary Embolism with Concurrent Fever

Immediate Anticoagulation

Initiate therapeutic anticoagulation without delay in all patients with acute PE/DVT and fever, unless there is active bleeding or an absolute contraindication. European Society of Cardiology (ESC) guideline recommends this approach. 8
In hemodynamically stable patients with fever, prefer low‑molecular‑weight heparin (LMWH) or fondaparinux over unfractionated heparin because they do not require laboratory monitoring and facilitate outpatient management once infection is excluded. ESC guideline. 9

Risk Stratification and Thrombolysis

For high‑risk PE (defined by shock or persistent hypotension), administer systemic thrombolytic therapy immediately unless the patient has a high bleeding risk or active infection with bleeding potential. ESC guideline. 8
For intermediate‑ or low‑risk PE (hemodynamically stable), systemic thrombolysis is not routinely indicated; therapeutic anticoagulation alone is sufficient. ESC guideline. 8

Oral Anticoagulant Selection

Prefer a direct oral anticoagulant (NOAC)—apixaban, rivaroxaban, edoxaban, or dabigatran—over warfarin when transitioning to oral therapy. ESC guideline. 8
NOACs should be avoided in patients with severe renal impairment (creatinine clearance < 25–30 mL/min) or antiphospholipid antibody syndrome; in these cases, warfarin is recommended. ESC guideline. 8
When warfarin is chosen, overlap with parenteral anticoagulation until the INR is 2.0–3.0 on two consecutive measurements taken at least 24 hours apart. ESC guideline. 8

Duration of Anticoagulation

All patients require a minimum of 3 months of therapeutic anticoagulation, irrespective of fever or concurrent infection. ESC guideline. 8
If the PE/DVT was provoked by a major transient risk factor (e.g., surgery, trauma), anticoagulation may be stopped after 3 months. ESC guideline. 8
For unprovoked PE/DVT, continue anticoagulation indefinitely when the bleeding risk is low‑to‑moderate; the annual recurrence risk exceeds 5 %. ESC guideline. 8
Patients with a prior recurrent VTE (≥ 1 previous episode) should remain on indefinite anticoagulation. ESC guideline. 8

Infection‑Related Considerations

Fever due to infection is not a contraindication to therapeutic anticoagulation unless the patient has active bleeding, hemorrhagic stroke, or a high bleeding risk directly related to the infection. ESC guideline. 10
Active infection with bleeding potential (e.g., infective endocarditis with mycotic aneurysm, hemorrhagic pneumonia) constitutes a relative contraindication to systemic thrombolysis; the decision must balance mortality risk from high‑risk PE against bleeding risk. ESC guideline. 10
When evaluating fever in a PE patient, clinicians should include infective endocarditis in the differential diagnosis and obtain appropriate cultures and imaging. ESC guideline. 10

Follow‑Up and Monitoring

Re‑evaluate all patients 3–6 months after the acute event to assess for chronic complications and to determine the need for continued anticoagulation. ESC guideline. 8
For patients on extended anticoagulation, perform regular assessments of drug tolerance, adherence, hepatic and renal function, and bleeding risk. ESC guideline. 8
Patients with persistent dyspnea and mismatched perfusion defects on a V/Q scan beyond 3 months should be referred to a pulmonary hypertension/CTEPH expert center for further evaluation. ESC guideline. 8

Use of Inferior Vena Cava (IVC) Filters

IVC filters should not be used routinely; they are reserved only for patients with absolute contraindications to anticoagulation. ESC guideline. 8

ESC Guideline Recommendations for Pulmonary Embolism in Patients with Severe Thrombocytopenia

Risk Stratification

High‑risk (massive) PE is defined by shock, persistent systolic blood pressure < 90 mmHg, cardiac arrest, or pulselessness. The presence of hypotension is the strongest predictor of poor outcome. 11
Intermediate‑risk PE includes patients who are hemodynamically stable but show right‑ventricular dysfunction on imaging. 11
Low‑risk PE comprises hemodynamically stable patients without right‑ventricular dysfunction. 11

Anticoagulation Strategy

In all PE patients with severe thrombocytopenia, immediate assessment of hemodynamic stability is required; anticoagulation should be started promptly unless there is active major bleeding. 11
Unfractionated heparin (UFH) is the preferred initial anticoagulant because it can be rapidly reversed with protamine and has a short half‑life, making it suitable for patients at high bleeding risk. UFH should be initiated without delay, even before definitive imaging confirmation. [11][12]
For intermediate‑ and low‑risk PE, therapeutic anticoagulation remains indicated despite severe thrombocytopenia, provided no active major bleeding is present. Systemic thrombolysis is not recommended in these hemodynamically stable patients due to an unacceptable bleeding risk. 11
When platelet counts are 30 000–50 000 µL, therapeutic UFH can be administered with close aPTT monitoring (every 4–6 h) and daily platelet checks. [11][12]
When platelet counts are < 30 000 µL, anticoagulation decisions must balance PE‑related mortality against bleeding risk; for symptomatic PE with substantial clot burden, anticoagulation is usually still warranted. 11

Thrombolysis and Surgical Options (Massive PE)

Systemic thrombolysis is the first‑line treatment for massive PE even in the setting of severe thrombocytopenia, because untreated massive PE carries a 15–25 % mortality that outweighs the bleeding risk. 11
Alteplase dosing: 50 mg IV bolus if cardiac arrest is imminent, or 100 mg infused over 90 minutes for a stable massive PE. 12
In life‑threatening PE, traditional contraindications to thrombolysis should be ignored; the mortality benefit supersedes bleeding concerns. 13
If thrombolysis is absolutely contraindicated or fails, surgical pulmonary embolectomy is the preferred alternative; catheter‑based techniques may be considered when surgery is unavailable. 11

Renal Function Considerations

UFH is the only parenteral anticoagulant recommended when creatinine clearance is < 30 mL/min, because LMWH and fondaparinux accumulate and increase bleeding risk in renal impairment. 11

Transition to Oral Anticoagulation

Once platelet count recovers above 50 000 µL and the patient is clinically stable, direct oral anticoagulants (NOACs) such as apixaban, rivaroxaban, edoxaban, or dabigatran are preferred. 11
NOACs should not be used when creatinine clearance is < 25–30 mL/min; in this scenario, warfarin is recommended instead. 11

Duration of Anticoagulation

A minimum of 3 months of anticoagulation is required for all PE cases, regardless of thrombocytopenia history. 11
Provoked PE (e.g., surgery, trauma, transient thrombocytopenia) – stop after 3 months. 11
Unprovoked or recurrent VTE – continue indefinitely if the bleeding risk remains acceptable. 11

Contraindications and Critical Pitfalls

Absolute contraindications to anticoagulation include active major bleeding (intracranial, gastrointestinal, retroperitoneal). 11
Never delay anticoagulation in high‑ or intermediate‑probability PE while awaiting platelet transfusion; the mortality risk from untreated PE exceeds bleeding risk. 11
Never withhold thrombolysis in massive PE solely because of thrombocytopenia; contraindications should be set aside in life‑threatening situations. 13

Pulmonary Embolism Anticoagulation Management Guidelines

Anticoagulation Initiation

All patients with acute pulmonary embolism should receive at least three months of therapeutic anticoagulation, followed by a mandatory reassessment at 3–6 months to decide on continuation based on provocation status and bleeding risk. – European Society of Cardiology (ESC) guideline 14
For all eligible patients, a direct oral anticoagulant (apixaban, rivaroxaban, edoxaban, or dabigatran) is preferred over warfarin. – ESC guideline 14
Absolute contraindications to NOACs are severe renal impairment (creatinine clearance < 25–30 mL/min) and antiphospholipid antibody syndrome; these patients must be managed with warfarin indefinitely. – ESC guideline 14
If warfarin is selected, it must be overlapped with low‑molecular‑weight heparin or fondaparinux until the INR is 2.0–3.0 on two consecutive measurements taken at least 24 h apart. – ESC guideline 14

Duration Decision Algorithm

Provoked PE (major transient/reversible risk factor such as recent surgery, trauma, immobilisation, or pregnancy): stop anticoagulation after three months. – ESC guideline 14
Unprovoked PE (no identifiable transient risk factor): extend anticoagulation indefinitely when bleeding risk is low‑to‑moderate; the annual recurrence risk exceeds 5 % and outweighs bleeding risk. – ESC guideline 14; International Society on Thrombosis and Haemostasis (ISTH) data [15][16]
Recurrent VTE (≥ 1 prior episode not linked to a transient factor): continue anticoagulation indefinitely. – ESC guideline 14
Antiphospholipid antibody syndrome: maintain warfarin therapy indefinitely (NOACs are contraindicated). – ESC guideline 14

Bleeding‑Risk Management

When bleeding risk is high at the 3–6‑month review, consider stopping anticoagulation even for unprovoked PE, or switch to a reduced NOAC dose (e.g., apixaban 2.5 mg bid or rivaroxaban 10 mg daily) for extended therapy. – ESC guideline 14
If bleeding risk is low‑to‑moderate, continue indefinite anticoagulation for unprovoked or recurrent PE. – ESC guideline 14

Follow‑up and Monitoring

A mandatory reassessment must occur at 3–6 months after the acute event to evaluate persistent dyspnoea, functional limitation, signs of chronic thromboembolic pulmonary hypertension (CTEPH), medication adherence, drug tolerance, and any bleeding events. – ESC guideline 14
Patients on extended anticoagulation require yearly visits to reassess bleeding risk, organ function, adherence, and the ongoing need for therapy. – ESC guideline 14
During each follow‑up, monitor for recurrent VTE or bleeding complications. – ESC guideline 14

Renal‑Function Considerations

When creatinine clearance falls below 30 mL/min, NOACs are contraindicated; patients should be switched to warfarin with a target INR of 2.0–3.0. – ESC guideline 14
Warfarin does not require renal dose adjustment, but regular INR monitoring remains mandatory. – ISTH guideline 16

CTEPH Screening

If persistent dyspnoea or functional limitation is present at the 3–6‑month review, perform ventilation‑perfusion (V/Q) scintigraphy to detect mismatched perfusion defects. – ESC guideline 14
Refer to a specialised CTEPH centre when V/Q scanning shows persistent perfusion defects. – ESC guideline 14

Criteria for Stopping Anticoagulation

Stop anticoagulation at three months when the PE was provoked by a major transient/reversible risk factor. – ESC guideline 14
Stop anticoagulation at three months when bleeding risk is prohibitively high and outweighs recurrence risk. – ISTH data [15][16]

Situations Requiring Continuation (Do Not Stop)

Unprovoked PE with low‑to‑moderate bleeding risk. – ESC guideline 14
History of ≥ 1 prior unprovoked VTE. – ESC guideline 14
Diagnosed antiphospholipid antibody syndrome. – ESC guideline 14

Critical Pitfalls (Safety Alerts)

Never discontinue anticoagulation at three months in unprovoked PE without weighing bleeding risk; the annual recurrence exceeds 5 %. – ESC guideline 14
Never use NOACs in severe renal impairment (< 25–30 mL/min) or in antiphospholipid antibody syndrome; warfarin is mandatory. – ESC guideline 14
Never lose patients to follow‑up after acute PE; routine reassessment at 3–6 months is essential for detecting CTEPH and guiding anticoagulation duration. – ESC guideline 14
Never ignore persistent dyspnoea, as it may indicate CTEPH requiring specialised evaluation. – ESC guideline 14

ESC Recommendations for Pulmonary Embolism Diagnosis and Management

Diagnosis

Clinical Probability Assessment

Base the diagnostic pathway on clinical probability using a validated prediction rule (e.g., Wells or Geneva score) before ordering any tests. 17, 18
Immediately assess for hemodynamic instability (shock or systolic BP < 90 mm Hg) to identify high‑risk PE that requires urgent reperfusion therapy. 17, 18

D‑dimer Testing

Measure D‑dimer only in out‑patient or emergency‑department patients with low or intermediate clinical probability (or PE‑unlikely) and use a highly sensitive assay. 17, 18, 19
Do not measure D‑dimer in patients with high clinical probability; a normal result does not safely exclude PE. 17, 18, 19
In low‑ or intermediate‑probability patients, a normal D‑dimer permits exclusion of PE without further testing. 17

Imaging Strategy

For suspected high‑risk PE, perform bedside echocardiography or emergency CTPA (depending on local availability). 17, 18
Accept a PE diagnosis when CTPA shows a segmental or more proximal filling defect in patients with intermediate or high clinical probability. 17, 18, 19
Reject a PE diagnosis when CTPA is normal in patients with low or intermediate clinical probability. 17, 18, 19
Use ventilation‑perfusion (V/Q) scintigraphy as a valid alternative when CTPA is contraindicated; a normal perfusion scan excludes PE. 17, 18
Do not perform CT venography as an adjunct to CTPA. 17, 18, 19
Do not use magnetic resonance angiography (MRA) to rule out PE. 17, 18, 19
Accept a VTE diagnosis when compression ultrasound demonstrates a proximal deep‑vein thrombosis in a patient with suspected PE. 17, 18, 19

Risk Stratification

High‑risk PE is defined by shock, persistent hypotension (systolic BP < 90 mm Hg for ≥15 min), or cardiac arrest. 17, 18
High‑risk patients have the highest early‑mortality risk and require immediate reperfusion therapy. 17, 18
Intermediate‑risk PE comprises hemodynamically stable patients with right‑ventricular (RV) dysfunction (on echo or CTPA) and/or elevated cardiac biomarkers (troponin, BNP/NT‑proBNP). 17, 18
Intermediate‑high risk: both RV dysfunction and biomarker elevation; intermediate‑low risk: one of the two. 17
Low‑risk PE: hemodynamically stable without RV dysfunction or biomarker elevation; these patients are candidates for early discharge and outpatient treatment. 17, 18

Acute‑Phase Treatment

High‑Risk PE

Initiate intravenous unfractionated heparin (UFH) without delay, including a weight‑adjusted bolus, even before imaging confirmation. 17, 18, 19
Administer systemic thrombolytic therapy immediately to all high‑risk PE patients who are not at high bleeding risk. 17, 18, 19
Perform surgical pulmonary embolectomy when thrombolysis is contraindicated or has failed. 17, 18, 19
Provide rescue thrombolysis if hemodynamic deterioration occurs despite anticoagulation. 17, 18, 19

Intermediate‑ and Low‑Risk PE

Start anticoagulation immediately in patients with high or intermediate clinical probability while diagnostic work‑up is ongoing. 17, 18, 19
When parenteral anticoagulation is needed in hemodynamically stable patients, prefer low‑molecular‑weight heparin (LMWH) or fondaparinux over UFH. 17, 18, 19
Do not use systemic thrombolysis as routine primary therapy in intermediate‑ or low‑risk PE. 17, 18, 19

Oral Anticoagulation Selection

Prefer a non‑vitamin‑K oral anticoagulant (NOAC: apixaban, dabigatran, edoxaban, rivaroxaban) over a vitamin‑K antagonist (VKA) when oral therapy is initiated. 17, 18, 19
As an alternative, use a VKA overlapped with parenteral anticoagulation until the INR reaches 2.5 (target 2.0–3.0). 17, 18
Do not use NOACs in patients with severe renal impairment (creatinine clearance < 25–30 mL/min) or antiphospholipid‑antibody syndrome; VKA is mandatory. 17, 18, 19

Inferior Vena Cava (IVC) Filters

Do not use IVC filters routinely; reserve them only for patients with absolute contraindications to anticoagulation. 17, 18, 19

Duration of Anticoagulation

Provide therapeutic anticoagulation for a minimum of 3 months to all patients with PE. 17, 18, 19
Discontinue oral anticoagulation after 3 months in patients whose first PE was provoked by a major transient/reversible risk factor (e.g., surgery, trauma, immobilization). 17, 18, 19
Re‑assess patients at 3–6 months and then yearly for drug tolerance, adherence, hepatic/renal function, and bleeding risk. 17, 18
Continue oral anticoagulation indefinitely in patients with recurrent VTE (≥ 1 prior episode) not related to a major transient risk factor. 17, 18, 19
In antiphospholipid‑antibody syndrome, continue VKA therapy indefinitely. 17, 18, 19
During pregnancy, use therapeutic fixed‑dose LMWH based on early‑pregnancy weight; NOACs are contraindicated in pregnancy and lactation. 17, 18, 19

Follow‑Up and CTEPH Screening

Re‑examine all patients 3–6 months after acute PE to evaluate persistent dyspnea, functional limitation, signs of VTE recurrence, cancer, or bleeding complications. 17, 19
Schedule regular follow‑up visits at yearly intervals for patients on extended anticoagulation. 17, 19
If persistent or new‑onset dyspnea or functional limitation is present, initiate a staged diagnostic work‑up to exclude chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease. 17, 19
Follow‑up imaging is not routinely required in asymptomatic patients but may be considered in those with risk factors for CTEPH (unprovoked PE, large perfusion defects, RV dysfunction, hypothyroidism, diabetes). 17

Critical Pitfalls to Avoid

Do not delay anticoagulation in high‑ or intermediate‑probability PE while awaiting diagnostic confirmation. 17, 18, 19
Do not measure D‑dimer in high‑clinical‑probability patients; proceed directly to imaging. 17, 18, 19
Do not use NOACs in severe renal impairment (< 25–30 mL/min) or antiphospholipid‑antibody syndrome; VKA is required. 17, 18, 19
Do not lose patients to follow‑up after acute PE; routine reassessment at 3–6 months is essential for detecting CTEPH and guiding anticoagulation duration. 17, 19

Pulmonary Embolism Diagnosis, Risk Stratification, and Treatment Guidelines (2026)

Diagnosis

Clinical Probability Assessment

Use a validated prediction rule (Wells or revised Geneva score) to stratify every patient with suspected pulmonary embolism into low, intermediate, or high clinical probability before ordering any tests. – European Society of Cardiology (ESC) guideline 20
Immediately assess for hemodynamic instability (shock, cardiac arrest, obstructive shock, or persistent hypotension) to identify high‑risk pulmonary embolism that requires urgent reperfusion therapy. – ESC guideline 21
The revised Geneva score assigns points as follows: prior venous thromboembolism (3), heart rate 75‑94 bpm (3) or ≥ 95 bpm (5), recent surgery or fracture (2), hemoptysis (2), active cancer (2), unilateral leg pain (3), pain on deep venous palpation with unilateral edema (4), age > 65 years (1). – ESC guideline 21
Score interpretation: low probability = 0‑3 points; intermediate = 4‑10 points; high ≥ 11 points (original Geneva). – ESC guideline 21

D‑dimer Testing

Measure D‑dimer only in patients with low or intermediate clinical probability using a highly sensitive assay; do not measure D‑dimer in high‑probability patients because a normal result does not safely exclude pulmonary embolism. – ESC guideline 20
Age‑adjusted D‑dimer cut‑offs (age × 10 µg/L for patients > 50 years) may be used as an alternative to a fixed cut‑off. – ESC guideline 20

Imaging Strategy

Computed tomography pulmonary angiography (CTPA) is the first‑choice imaging test for hemodynamically stable patients with an elevated D‑dimer or high clinical probability. – ESC guideline 20
Accept a pulmonary embolism diagnosis when CTPA shows a segmental or more proximal filling defect in patients with intermediate or high clinical probability. – ESC guideline 20
Reject a pulmonary embolism diagnosis when CTPA is normal in patients with low or intermediate clinical probability. – ESC guideline 20
Ventilation‑perfusion (V/Q) scintigraphy is a valid alternative when CTPA is contraindicated (e.g., contrast allergy, renal impairment); a normal perfusion scan excludes pulmonary embolism. – ESC guideline 20
Do not perform CT venography as an adjunct to CTPA. – ESC guideline 20
Do not use magnetic resonance angiography to rule out pulmonary embolism. – ESC guideline 20
Identification of a proximal deep‑vein thrombosis by compression ultrasound in a patient with suspected pulmonary embolism confirms venous thromboembolism and justifies anticoagulation. – ESC guideline 20

Avoiding Overuse of Testing

The Pulmonary Embolism Rule‑out Criteria (PERC) – age < 50 years, pulse < 100 bpm, SaO₂ > 94 %, no unilateral leg swelling, no hemoptysis, no recent trauma/surgery, no prior VTE, no oral hormone use – can identify emergency‑department patients with such low probability that diagnostic work‑up should not be initiated. – ESC guideline 21

Risk Stratification

High‑risk pulmonary embolism is defined by the presence of shock, cardiac arrest, obstructive shock, or persistent hypotension and carries an early mortality that may exceed 30 %. – ESC guideline 21
Intermediate‑risk pulmonary embolism comprises hemodynamically stable patients with evidence of right‑ventricular (RV) dysfunction (on echocardiography or CTPA) and/or elevated cardiac biomarkers (troponin, BNP/NT‑proBNP). – ESC guideline 20

Acute‑Phase Treatment

High‑Risk Pulmonary Embolism

Administer systemic thrombolytic therapy immediately to all high‑risk pulmonary embolism patients who do not have a high bleeding risk. – ESC guideline 20
Surgical pulmonary embolectomy is indicated when thrombolysis is absolutely contraindicated or fails to improve hemodynamics within one hour. – ESC guideline 20
Provide rescue thrombolysis if hemodynamic deterioration occurs despite anticoagulation. – ESC guideline 20

Anticoagulation for High‑ and Intermediate‑Probability Patients

Start anticoagulation immediately in patients with high or intermediate clinical probability while diagnostic work‑up proceeds. – ESC guideline 20
For parenteral anticoagulation in hemodynamically stable patients, prefer low‑molecular‑weight heparin (LMWH) or fondaparinux over unfractionated heparin (UFH). – ESC guideline 20
Do not use systemic thrombolysis as routine primary treatment in intermediate‑ or low‑risk pulmonary embolism. – ESC guideline 20

Oral Anticoagulation Selection

Prefer a non‑vitamin‑K oral anticoagulant (NOAC) – apixaban, rivaroxaban, edoxaban, or dabigatran – over a vitamin K antagonist (VKA) when initiating oral therapy. – ESC guideline 20
If a VKA (warfarin) is chosen, overlap with parenteral anticoagulation until the INR reaches 2.0‑3.0 on two consecutive measurements taken at least 24 hours apart (target INR ≈ 2.5). – ESC guideline 20
Do not use NOACs in patients with severe renal impairment (creatinine clearance < 25‑30 mL/min) or antiphospholipid antibody syndrome; these patients must receive a VKA indefinitely. – ESC guideline 20
For cancer‑associated pulmonary embolism, edoxaban or rivaroxaban may be considered as alternatives to LMWH, with caution in gastrointestinal cancers due to increased bleeding risk. – ESC guideline 20
During pregnancy, use therapeutic fixed‑dose LMWH based on early‑pregnancy weight; NOACs are contraindicated in pregnancy and lactation. – ESC guideline 20

Duration of Anticoagulation

All patients with pulmonary embolism require therapeutic anticoagulation for a minimum of 3 months, followed by mandatory reassessment at 3‑6 months to decide on continuation. – ESC guideline 20
Discontinue anticoagulation after 3 months in patients whose first pulmonary embolism was provoked by a major transient/reversible risk factor (e.g., surgery, trauma, immobilization, pregnancy). – ESC guideline 20
Extend anticoagulation indefinitely beyond 3 months for unprovoked pulmonary embolism when bleeding risk is low‑to‑moderate; the annual recurrence risk exceeds 5 %. – ESC guideline 20
The 2019 ESC guideline no longer supports the “provoked” versus “unprovoked” terminology; instead, classify risk factors as high, intermediate, or low recurrence risk. – ESC guideline 20
After the first 6 months, a reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg daily) may be used for extended anticoagulation. – ESC guideline 20
Continue oral anticoagulation indefinitely in patients with recurrent venous thromboembolism (≥ 1 prior episode) not related to a major transient risk factor. – ESC guideline 20
Continue VKA therapy indefinitely in patients with antiphospholipid antibody syndrome; NOACs are contraindicated. – ESC guideline 20
Re‑assess patients at 3‑6 months and then yearly for drug tolerance, adherence, hepatic/renal function, and bleeding risk. – ESC guideline 20
Use VTE recurrence scores and bleeding scores in parallel to guide decisions about extended anticoagulation. – ESC guideline 20

Inferior Vena Cava (IVC) Filter Placement

Do not routinely place IVC filters; reserve them only for patients with absolute contraindications to anticoagulation (e.g., active major bleeding) or who experience recurrent pulmonary embolism despite adequate anticoagulation. – ESC guideline 20

Follow‑Up and CTEPH Screening

Re‑examine all patients 3‑6 months after acute pulmonary embolism to evaluate persistent dyspnea, functional limitation, signs of VTE recurrence, cancer, or bleeding complications. – ESC guideline 20
An integrated model of patient care after pulmonary embolism is proposed to ensure optimal transition from hospital to community care. – ESC guideline 20
If persistent or new‑onset dyspnea or functional limitation is present at the 3‑6 month review, perform ventilation‑perfusion scintigraphy to detect mismatched perfusion defects suggestive of chronic thromboembolic pulmonary hypertension (CTEPH). – ESC guideline 20
Refer symptomatic patients with persistent perfusion defects to a specialized CTEPH center, incorporating echocardiography, natriuretic peptide levels, and/or cardiopulmonary exercise testing. – ESC guideline 20

Critical Pitfalls to Avoid

Never delay anticoagulation in high‑ or intermediate‑probability pulmonary embolism while awaiting diagnostic confirmation. – ESC guideline 20
Never measure D‑dimer in high‑clinical‑probability patients; proceed directly to imaging. – ESC guideline 20
Never use NOACs in severe renal impairment (< 25‑30 mL/min) or antiphospholipid antibody syndrome; a VKA is mandatory. – ESC guideline 20
Never lose patients to follow‑up after acute pulmonary embolism; routine reassessment at 3‑6 months is essential for detecting CTEPH and guiding anticoagulation duration. – ESC guideline 20
Never ignore persistent dyspnea, as it may indicate CTEPH requiring specialized evaluation. – ESC guideline 20

Home Management of Bilateral Pulmonary Embolism (Outpatient DOAC Therapy)

Eligibility for Outpatient Treatment

Hemodynamically stable patients with bilateral pulmonary embolism, no contraindications to oral anticoagulation, adequate home support, no need for supplemental oxygen, and a low‑risk score on validated tools (PESI or sPESI) are appropriate for home treatment with a direct oral anticoagulant (DOAC). 22
The Pulmonary Embolism Severity Index (PESI) or simplified PESI (sPESI) should be used to identify low‑risk patients; these scores have moderate predictive ability for adverse outcomes and complement clinical judgment. 22
Bilateral emboli alone do not preclude outpatient management; the decisive factors are hemodynamic stability, oxygen saturation, and absence of right‑ventricular strain. 22

Absolute Contraindications to Home Management

Hemodynamic instability (systolic blood pressure < 90 mm Hg, shock, or requirement for vasopressors). 22
Hypoxia requiring supplemental oxygen (room‑air SaO₂ < 90 %). [22][23]
Active major bleeding or a high bleeding‑risk profile. 22
Need for intravenous analgesia. 22
Any other medical condition that mandates hospitalization (e.g., severe infection, uncontrolled arrhythmia). 22
Insufficient social support or inability to secure medication access/poor adherence history. 22

First‑Line Anticoagulation Strategy

Initiate a DOAC (rivaroxaban or apixaban) immediately; these agents do not require an initial parenteral lead‑in and simplify outpatient care. 22

DOAC Contraindications & Alternative Regimens

DOACs should be avoided in patients with severe renal impairment (creatinine clearance < 25–30 mL/min), antiphospholipid antibody syndrome, pregnancy or lactation, and active cancer (where low‑molecular‑weight heparin monotherapy is preferred). 22
When DOACs are contraindicated, treat with therapeutic low‑molecular‑weight heparin (e.g., enoxaparin 1 mg/kg subcutaneously twice daily) overlapped with warfarin until the INR is 2.0–3.0 on two consecutive days. 22

Duration of Anticoagulation

All patients require a minimum of 3 months of therapeutic anticoagulation regardless of treatment setting. 22
Anticoagulation may be stopped after 3 months if the embolism was provoked by a major transient/reversible risk factor (e.g., recent surgery, trauma, immobilization). 22
For unprovoked bilateral PE in patients with low‑to‑moderate bleeding risk, indefinite anticoagulation is recommended because the annual recurrence risk exceeds 5 %. 22
Patients with a prior recurrent venous thrombo‑embolism (≥ 1 previous episode) or antiphospholipid syndrome should receive indefinite anticoagulation. 22

Patient Education & Safety Instructions

Educate patients to seek immediate emergency care for signs of recurrent PE (sudden dyspnea, chest pain, hemoptysis). 23
Instruct patients to call emergency services promptly if they experience major bleeding (e.g., intracranial, gastrointestinal, or retroperitoneal hemorrhage). 22

Avoidance of Routine Interventions

Inferior vena cava (IVC) filters should not be used routinely; they are reserved only for patients with absolute contraindications to anticoagulation. 22
Hospital admission decisions should be based on hemodynamic status, oxygen requirements, right‑ventricular function, and social support—not merely on the presence of bilateral emboli. 22

ESC Guidelines for Pulmonary Embolism Diagnosis and Management

Immediate Diagnostic Approach

Clinical probability should be assessed with a validated rule (Wells or revised Geneva) before any testing to categorize patients as low, intermediate, or high risk. 24
Hemodynamic instability (shock, cardiac arrest, or systolic BP < 90 mmHg ≥ 15 min) identifies high‑risk PE that requires urgent reperfusion therapy. 25
D‑dimer testing is reserved for patients with low or intermediate clinical probability and must be performed with a highly sensitive assay. 24
In high‑probability patients, D‑dimer should not be measured; imaging should be pursued directly. 24
Age‑adjusted D‑dimer thresholds (age × 10 µg/L for patients > 50 y) may replace fixed cut‑offs. 26
Computed tomography pulmonary angiography (CTPA) is the first‑line imaging test for hemodynamically stable patients with elevated D‑dimer or high clinical probability. 24
A PE diagnosis is confirmed when CTPA shows segmental or more proximal filling defects in patients with intermediate or high clinical probability. 24
A normal CTPA excludes PE in patients with low or intermediate clinical probability. 24
Ventilation‑perfusion (V/Q) scintigraphy is an acceptable alternative when CTPA is contraindicated (e.g., contrast allergy, renal impairment); a normal perfusion scan rules out PE. 24
Compression ultrasound that demonstrates proximal deep‑vein thrombosis confirms venous thromboembolism and justifies anticoagulation without further PE imaging. 24

Risk Stratification Framework

High‑risk (massive) PE is defined by shock, cardiac arrest, obstructive shock, or persistent hypotension (systolic < 90 mmHg ≥ 15 min). 24
Early mortality in untreated high‑risk PE can exceed 30 %. 24
Bedside transthoracic echocardiography should be performed immediately in suspected high‑risk PE to differentiate it from other acute life‑threatening conditions. 25
Intermediate‑risk PE includes hemodynamically stable patients with right‑ventricular (RV) dysfunction on echo or CTPA and/or elevated cardiac biomarkers (troponin, BNP/NT‑proBNP). 24
Intermediate‑high risk: both RV dysfunction and biomarker elevation present; intermediate‑low risk: only one of the two present. 24
Low‑risk PE: hemodynamically stable, no RV dysfunction, and no biomarker elevation; these patients are candidates for early discharge and outpatient treatment. 24
The simplified Pulmonary Embolism Severity Index (sPESI) score of 0 identifies patients with a 30‑day mortality < 1 %. 24

Acute‑Phase Treatment

High‑Risk PE

Initiate intravenous unfractionated heparin (weight‑adjusted bolus 80 U/kg, then 18 U/kg/h) without delay, even before imaging confirmation. 24
Systemic thrombolysis should be given immediately to all high‑risk PE patients without a high bleeding risk. 25
Alteplase dosing: 100 mg infused over 2 h (standard) or 0.6 mg/kg over 15 min (max 50 mg) for extreme instability. (dose recommendation cited in guideline text)
Surgical pulmonary embolectomy is indicated when thrombolysis is absolutely contraindicated or fails to improve hemodynamics within 1 h. 25
Rescue thrombolysis is advised if hemodynamic deterioration occurs despite anticoagulation. 25
Catheter‑directed therapy may be considered as an alternative to rescue thrombolysis for deteriorating patients. 26
Extracorporeal membrane oxygenation (ECMO) can be combined with surgical or catheter‑directed therapy in refractory circulatory collapse or cardiac arrest. 26

Intermediate‑ and Low‑Risk PE

Start anticoagulation immediately while diagnostic work‑up continues in patients with high or intermediate clinical probability. 25
For parenteral anticoagulation in hemodynamically stable patients, low‑molecular‑weight heparin (LMWH) or fondaparinux is preferred over unfractionated heparin. 24
Systemic thrombolysis is not recommended as routine primary therapy for intermediate‑ or low‑risk PE because of excessive bleeding risk. 25

Oral Anticoagulation Selection

Non‑vitamin K oral anticoagulants (NOACs) – apixaban, rivaroxaban, edoxaban, dabigatran – are preferred over warfarin for initiating oral therapy. 25
If warfarin is used, it must be overlapped with parenteral anticoagulation until the INR is 2.0–3.0 on two consecutive measurements ≥ 24 h apart (target INR ≈ 2.5). 24
NOACs are contraindicated in patients with severe renal impairment (creatinine clearance < 25–30 mL/min) or antiphospholipid antibody syndrome; these patients require warfarin indefinitely. 25
For cancer‑associated PE, edoxaban or rivaroxaban may be used instead of LMWH, except in gastrointestinal cancers where bleeding risk is higher. 26

Duration of Anticoagulation

All patients require at least 3 months of therapeutic anticoagulation, irrespective of PE etiology. 25
Provoked PE (major transient/reversible risk factor such as surgery, trauma, or immobilization) – discontinue anticoagulation after 3 months. 25
Unprovoked PE – extend anticoagulation indefinitely when bleeding risk is low‑to‑moderate; annual recurrence risk exceeds 5 %. 25
After 6 months, a reduced dose of apixaban (2.5 mg bid) or rivaroxaban (10 mg daily) may be used for extended therapy. 26
Patients with recurrent VTE (≥ 1 prior episode) not linked to a major transient factor should continue oral anticoagulation indefinitely. 25
Antiphospholipid antibody syndrome – lifelong warfarin therapy; NOACs are prohibited. 25
Pregnancy – therapeutic fixed‑dose LMWH based on early‑pregnancy weight; NOACs are contraindicated. 24

Inferior Vena Cava (IVC) Filter Placement

Routine IVC filter placement is not recommended; filters are reserved for patients with absolute contraindications to anticoagulation (active major bleeding) or recurrent PE despite adequate anticoagulation. 25

Post‑PE Care and Long‑Term Sequelae

A routine clinical review 3–6 months after acute PE is advised to evaluate dyspnea, functional limitation, VTE recurrence, cancer, or bleeding complications. 25
An integrated care model should be employed to ensure smooth transition from hospital to ambulatory follow‑up. 25
For patients on extended anticoagulation, annual reassessment of drug tolerance, adherence, hepatic and renal function, and bleeding risk is recommended. 24

CTEPH Screening

If dyspnea or functional limitation persists at the 3–6 month review, perform a V/Q scan to detect mismatched perfusion defects suggestive of chronic thromboembolic pulmonary hypertension (CTEPH). 25
Patients with abnormal V/Q findings > 3 months after PE should be referred to a pulmonary hypertension/CTEPH expert center for further evaluation (echocardiography, natriuretic peptides, cardiopulmonary exercise testing). 25
Routine follow‑up imaging is not required in asymptomatic patients, but may be considered in those with risk factors for CTEPH. 25

Pulmonary Embolism Response Teams (PERT)

Establish multidisciplinary PERTs for managing high‑risk and selected intermediate‑risk PE cases, tailored to institutional resources and expertise. 26
PERTs facilitate rapid selection of optimal reperfusion strategy (systemic thrombolysis, surgical embolectomy, or catheter‑directed therapy). 25

Critical Pitfalls to Avoid

Do not delay anticoagulation in high‑ or intermediate‑probability PE while awaiting diagnostic confirmation. 25
Do not measure D‑dimer in high‑clinical‑probability patients; proceed directly to imaging. 24
Do not use NOACs in severe renal impairment or antiphospholipid antibody syndrome; warfarin is mandatory. 25
Do not discontinue anticoagulation before 3 months under any circumstance, as early cessation raises recurrence risk. 25
Do not overlook persistent dyspnea after PE; it may indicate CTEPH requiring specialized evaluation. 25

Management of Provoked Bilateral Segmental Pulmonary Embolism

Anticoagulant Selection and Dosing

Rivaroxaban 15 mg twice daily for 21 days, then 20 mg once daily, or apixaban 10 mg twice daily for 7 days, then 5 mg twice daily, are the preferred first‑line oral agents for a healthy adult with normal renal function and a provoked bilateral segmental PE; therapy is stopped after exactly 3 months. 27
Rivaroxaban and apixaban are favored over warfarin because they do not require an initial parenteral bridge, simplify outpatient management, and have demonstrated non‑inferiority to warfarin with lower major‑bleeding rates. 27
Dabigatran and edoxaban require a 5–10‑day therapeutic low‑molecular‑weight heparin (LMWH) lead‑in before the oral agent can be started, making them less suitable for immediate home discharge. 27

Minimum Duration of Anticoagulation

All patients with PE need at least 3 months of therapeutic anticoagulation. 27, 28, 29
Because the PE is provoked by a major transient/reversible risk factor, anticoagulation should be discontinued after 3 months; the post‑treatment annual recurrence risk is ≈2.5 % and does not justify indefinite therapy. 27, 28, 29
Extending anticoagulation beyond 3 months in provoked PE (e.g., after surgery, trauma, or immobilization) provides no benefit, as the annual recurrence risk is <1 % and bleeding risk increases. 27, 28, 29

Absolute Contraindications to Direct Oral Anticoagulants (DOACs)

Severe renal impairment (creatinine clearance <25–30 mL/min) is an absolute contraindication to all DOACs; warfarin should be used instead. 27
Antiphospholipid antibody syndrome is a contraindication to DOACs because they are associated with higher recurrent thrombosis rates (≈5.8–10.7 % per year); warfarin (target INR 2.0–3.0) is mandatory. 27
Pregnancy or lactation contraindicates DOACs due to placental transfer and excretion in breast milk; therapeutic LMWH should be used throughout pregnancy and for ≥6 weeks postpartum. 27
Active cancer generally warrants LMWH monotherapy for ≥6 months; DOACs (edoxaban or rivaroxaban) may be considered only in non‑gastrointestinal malignancies. 27

Warfarin Alternative When DOACs Are Contraindicated

Initiate therapeutic LMWH (enoxaparin 1 mg/kg subcutaneously twice daily) and overlap with warfarin until the INR is 2.0–3.0 on two consecutive measurements ≥24 hours apart. 27
Continue warfarin for exactly 3 months with a target INR of 2.5 (acceptable range 2.0–3.0), then discontinue. 27

Follow‑Up and Reassessment

Schedule a mandatory clinical review at 3 months to confirm resolution of the provoking factor, evaluate for persistent dyspnea (possible chronic thromboembolic pulmonary hypertension), and discontinue anticoagulation. 27

Critical Pitfalls to Avoid

Do not extend anticoagulation beyond 3 months in provoked PE; the low recurrence risk (<1 % annually) does not outweigh bleeding risk. 27, 28, 29
Do not use DOACs in patients with severe renal impairment or antiphospholipid syndrome; warfarin is required. 27
Do not substitute dabigatran or edoxaban without the required 5–10‑day LMWH lead‑in; these agents are unsuitable for immediate home discharge. 27
Do not place an inferior vena cava (IVC) filter in routine PE management; filters are reserved only for patients with absolute contraindications to anticoagulation (e.g., active major bleeding). 27
Do not delay anticoagulation while awaiting diagnostic confirmation in patients with high or intermediate clinical probability of PE; treatment should be initiated promptly. 27